Amarin current debt payment is 10% of Net Revenue (Pharmakon) and 3.5% interest on $150M till January 2017. $31,266k will be payable in January 2017 IF the Holders will request.
If scripts don't grow fast enough Amarin will dilute shares once again.
The current cash in hand (w/o add. milestone from Eddingpharm and w/o new ex-US deal) is more than enough till interim readout, so I do not expect any dilution before that. Nobody expect a significant (%) increase before Q4 (expect over-optimistics): we will see. Top of it Q1 will be interesting as coverage: we are approaching (in) the period when HCP prepare the next year formularies.
To reach bottom line break-even, the script# should be 45k, BUT if R-IT will be stopped @ interim 32k will be enough for it. As the stop could be happen in Q2 2016 as the earliest it is (w 1A communication, increased coverage) possible.
- - - - - z- I do not know, I am an accountant only and speak Hunglish ... but settlement discussion is ongoing ...
News 
Market Data 
Discover 
